Acotec Scientific Holdings Limited (HKG:6669)

Market Cap	2.94B +33.5%
Revenue (ttm)	717.35M +20.7%
Net Income	132.63M +128.0%
EPS	0.43 +129.4%
Shares Out	313.39M
PE Ratio	21.59
Forward PE	18.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	297,525
Average Volume	327,844
Open	9.55
Previous Close	9.37
Day's Range	9.21 - 9.61
52-Week Range	7.07 - 15.47
Beta	-0.02
RSI	33.27
Earnings Date	May 26, 2026

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 653
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6669

Financial Performance

In 2025, HKG:6669's revenue was 644.63 million, an increase of 20.72% compared to the previous year's 533.99 million. Earnings were 119.18 million, an increase of 127.97%.

Financial numbers in CNY